bell
The current prices are delayed by 15 mins, login to check live prices.
Mankind Pharma Ltd share price logo

Mankind Pharma Ltd

(MANKIND)

₹2559▲2.2%

as on 04:01PM, 03 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Mankind Pharma Ltd Analyst Rating

based on 16 analysts

BUY

75.00%

Buy

18.75%

Hold

6.25%

Sell

Based on 16 analysts offering long term price targets for Mankind Pharma Ltd. An average target of ₹2814.88

Source: S&P Global Market Intelligence

Mankind Pharma Ltd Share analysis

Mankind Pharma Ltd price forecast by 16 analysts

Upside of7.58%

High

₹3300

Target

₹2814.88

Low

₹2275

Mankind Pharma Ltd target price ₹2814.88, a slight upside of 7.58% compared to current price of ₹2559. According to 16 analysts rating.

Source: S&P Global Market Intelligence

Mankind Pharma Ltd Performance

  • Day's Low

    Day's High

    ₹2,552
    ₹2,637.35

  • 52 Week's Low

    52 Week's High

    ₹1,821
    ₹2,874
1 Month Return-4.2 %
3 Month Return+ 9.42 %
1 Year Return+ 36 %
Previous Close₹2,616.45
Open₹2,634.55
Volume6.36L
Upper Circuit-
Lower Circuit-
Market Cap₹1,04,831.25Cr

Mankind Pharma Ltd Key Statistics

P/E Ratio49.56
PEG Ratio3.56
Market Cap₹1,04,831.25 Cr
P/B Ratio9.56
EPS48.47
Dividend Yield0
SectorPharmaceuticals
ROE20.95

Mankind Pharma Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Mankind Pharma Ltd
Mankind Pharma Ltd
BUY₹1,04,831.25 Cr16.79%0.51₹1,941 Cr₹10,334 Cr
Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd
BUY₹4,33,931.73 Cr63.42%0.68₹9,648 Cr₹48,496 Cr
Divis Laboratories Ltd
Divis Laboratories Ltd
HOLD₹1,66,059.89 Cr49.69%0.50₹1,600 Cr₹7,845 Cr
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd
HOLD₹1,01,940.95 Cr22.74%0.52₹5,577 Cr₹28,011 Cr
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd
BUY₹1,13,006.93 Cr49.07%0.67₹1,656 Cr₹10,727 Cr
See all

Mankind Pharma Ltd Mutual Fund Holdings

About Mankind Pharma Ltd

Mankind Pharma Ltd. was established in 1991 as a Private Limited Company. In 2005 it was converted to a Public Limited Company and the name changed to Mankind Pharma Limited. The Company is engaged in the development, manufacturing and marketing of a range of pharmaceuticals and consumer healthcare products, and is active in acute and chronic therapeutic areas such as anti-infectives, cardiovascular and gastrointestinal treatments, antidiabetic and neuro/CNS medicines, vitamins, minerals and nutrients. In 2004, they entered the chronic pharmaceutical segment, and have added further products over the years, including ophthalmic products, consumer healthcare products, animal healthcare products and specialty therapeutic divisions. They operate 23 manufacturing facilities across India and had 2181 manufacturing personnel as of March 31, 2021. It is now planning to raise capital through the public offering of 40058844 equity shares, with a total installed capacity of 40.77 billion units across a range of products.

Share Price: ₹2559.00 per share as on 03 Dec, 2024 04:01 PM
Market Capitalisation: ₹1,04,831.25Cr as of today
Revenue: ₹3,076.51Cr as on September 2024 (Q3 24)
Net Profit: ₹658.88Cr as on September 2024 (Q3 24)
Listing date: 09 May, 2023
Chairperson Name: RAMESH CHAND JUNEJA
OrganisationMankind Pharma Ltd
HeadquartersNew Delhi
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Mankind Pharma Ltd

  • Mankind Pharma Continues Upward Trend - 02 Dec, 2024

    Mankind Pharma Ltd has risen for the third consecutive session, trading at Rs 2609.95, up 1.9%. The stock is up 35.66% over the past year, despite a recent 4.44% decline in the last month. The Nifty Pharma index has also seen a slight decrease of 0.69% in the same period.

  • BofA Raises Concerns on Mankind Pharma Outlook - 28 Nov, 2024

    Bank of America has expressed concerns regarding structural challenges in the domestic pharmaceutical sector, highlighting margin risks and a muted growth outlook for Mankind Pharma. The brokerage has maintained an Underperform rating due to operational hurdles.

  • Mankind Pharma Shares Decline, Market Cap Drops - 21 Nov, 2024

    Mankind Pharma's shares fell by 2.15%, closing at Rs 2,519, resulting in a market cap loss of Rs 2,219 crore. This decline reflects profit booking and subdued investor interest in the pharmaceutical sector.

  • Mankind Pharma Market Cap Rises by Rs 742 Crore - 18 Nov, 2024

    On November 18, 2024, Mankind Pharma's shares increased by 0.71%, leading to a market cap rise of Rs 742 crore, totaling Rs 1,04,808.51 crore. The stock reflects strong investor confidence in the pharmaceutical sector.

  • Mankind Pharma Pledges Stake for NCD Financing - 15 Nov, 2024

    Mankind Pharma has pledged 39.68% of its equity stake in Bharat Serums and Vaccines to secure ₹5,000 crore in non-convertible debentures. This move aims to support the company's strategic initiatives and growth plans while adhering to regulatory standards.

  • Mankind Pharma Shares Rebound After Decline - 14 Nov, 2024

    Mankind Pharma shares rebounded by 3.87% after a five-day losing streak, closing at ₹2,600.00. The market cap increased by ₹2,710.87 crore, reflecting renewed investor interest.

  • Mankind Pharma Market Cap Rises with Stock Surge - 12 Nov, 2024

    On November 12, 2024, Mankind Pharma's stock increased by 0.90%, reaching Rs 2,670.35, resulting in a market cap gain of Rs 964 crore, reflecting strong investor confidence in the pharmaceutical sector.

  • Mankind Pharma Targets Debt-Free Status by 2027 - 08 Nov, 2024

    Mankind Pharma plans to eliminate its debt within three years, reporting a significant 28.9% increase in net profit for Q2 FY25, alongside a 13.6% revenue growth.

  • Mankind Pharma Reports Strong Q2 Growth and Ratings Reaffirmation - 06 Nov, 2024

    Mankind Pharma's Q2 FY25 net profit surged 30% YoY, with shares rising 6% after a 29% profit growth announcement. The company also received reaffirmation of credit ratings from CRISIL, indicating strong financial health.

  • Mankind Pharma Reports Strong Q2 Earnings Growth - 05 Nov, 2024

    Mankind Pharma's Q2 results reveal a 29% increase in net profit to Rs 659 crore, driven by strong demand in chronic illness drugs and robust revenue growth. Analysts remain optimistic, with most recommending a buy on the stock.

  • Mankind Pharma Celebrates Contributions of Notable Doctors - 03 Nov, 2024

    A new documentary titled 'The Mountain Man,' produced by Mankind Pharma, honors the legacy of Dr. J S Titiyal and other significant Indian doctors for their contributions to society.

Insights on Mankind Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 2.53K Cr → 3.18K Cr (in ₹), with an average increase of 10.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, 453.76 Cr → 653.47 Cr (in ₹), with an average increase of 11.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, MANKIND stock has moved up by 9.4%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 11.58% to 12.37% in Sep 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 74.87% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 3.61% to 2.86% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 7.37% to 6.99% in Sep 2024 quarter

Mankind Pharma Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹2,708.10Cr (-)₹2,606.96Cr (↓3.73%)₹2,441.10Cr (↓6.36%)₹2,893.42Cr (↑18.53%)₹3,076.51Cr (↑6.33%)
Net Income₹511.18Cr (-)₹459.81Cr (↓10.05%)₹476.59Cr (↑3.65%)₹543.07Cr (↑13.95%)₹658.88Cr (↑21.33%)
Net Profit Margin18.88% (-)17.64% (↓6.57%)19.52% (↑10.66%)18.77% (↓3.84%)21.42% (↑14.12%)
Value in ₹ crore
Details2021202220232024
Total Assets₹5,989.77Cr (-)₹9,103.97Cr (↑51.99%)₹9,634.50Cr (↑5.83%)₹11,765.16Cr (↑22.11%)
Total Liabilities₹1,255.50Cr (-)₹2,563.52Cr (↑104.18%)₹1,850.59Cr (↓27.81%)₹2,141.35Cr (↑15.71%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹959.61Cr (-)₹983.38Cr (↑2.48%)₹821.44Cr (↓16.47%)₹1,798.99Cr (↑119.00%)₹1,982.97Cr (↑10.23%)

Index Inclusions

BSE 200

₹11,280.05

0.77 (▲86.13%)

Nifty 500

₹23,020.85

0.81 (▲185%)

S&P BSE Largecap

₹9,521.53

0.75 (▲70.94%)

S&P BSE 250 LargeMidCap

₹10,706.91

0.79 (▲83.72%)

Nifty Midcap 150

₹21,291.35

0.88 (▲185.4%)

BSE Healthcare

₹44,313.66

0.27 (▲117.67%)

Nifty Midcap 100

₹57,509.00

0.89 (▲508.15%)

BSE 500

₹36,246.75

0.8 (▲289.35%)

NIFTY PHARMA

₹22,445.70

-0.02 (▲-4.5%)

S&P BSE 100 LargeCap TMC

₹9,144.61

0.76 (▲68.75%)

Nifty LargeMidcap 250

₹16,052.90

0.83 (▲131.65%)

Nifty 200

₹13,825.85

0.79 (▲108.9%)

Nifty MidSmallcap 400

₹20,172.55

0.9 (▲180%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Mankind Pharma Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
74.87%
0.00
Foreign Institutions
12.37%
6.83
Mutual Funds
6.99%
-5.15
Retail Investors
2.86%
-20.68
Others
2.91%
13.02

Mankind Pharma Ltd Key Indicators

Details20202021202220232024
Return On Equity %28.5325.8624.6517.4320.95
Details2021202220232024
Return On Assets %21.1315.7513.316.26
Details2024
Book Value Per Share (₹)233.73
Details2024
Earning Per Share (₹)48.47

Mankind Pharma Ltd Valuation

Mankind Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (40.63x)

August 5, 2024

Today (49.56x)

December 2, 2024

Industry (56.86x)

December 2, 2024

Highest (55.81x)

September 24, 2024

LowHigh

Mankind Pharma Ltd Earnings and Dividends

  • Mankind Pharma Ltd Earnings Results

    Mankind Pharma Ltd’s net profit jumped 30.43% since last year same period to ₹653.47Cr in the Q2 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated 21.8% jump in its net profits since last 3-months.

    Read More about Earnings Results

Mankind Pharma Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Mankind Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

FAQs on Mankind Pharma Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Mankind Pharma Ltd shares.

Mankind Pharma Ltd (MANKIND) share price today is ₹2559

Mankind Pharma Ltd is listed on NSE

Mankind Pharma Ltd is listed on BSE

  • Today’s highest price of Mankind Pharma Ltd is ₹2637.35.
  • Today’s lowest price of Mankind Pharma Ltd is ₹2552.

PE Ratio of Mankind Pharma Ltd is 49.56

PE ratio = Mankind Pharma Ltd Market price per share / Mankind Pharma Ltd Earnings per share

Today’s traded volume of Mankind Pharma Ltd(MANKIND) is 6.36L.

Today’s market capitalisation of Mankind Pharma Ltd(MANKIND) is ₹104831.25Cr.

Mankind Pharma Ltd(MANKINDPrice
52 Week High
₹2874
52 Week Low
₹1821

Mankind Pharma Ltd(MANKIND) share price is ₹2559. It is down -10.96% from its 52 Week High price of ₹2874

Mankind Pharma Ltd(MANKIND) share price is ₹2559. It is up 40.53% from its 52 Week Low price of ₹1821

Mankind Pharma Ltd(MANKINDReturns
1 Day Returns
-57.45%
1 Month Returns
-4.2%
3 Month Returns
9.42%
1 Year Returns
36%